# US 2026/0306422 A1 · Perfluorocarbon compositions, systems, and methods for ischemic, inflammatory, infectuous, transplant, and other medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306422 A1
- Document ID: US20260306422A1
- Status: Published application
- Kind: A1
- Application number: 19/298,998
- Filed: 2025-08-13
- Published: 2026-10-08
- Earliest claimed: 2024-08-13
- Inventors: MATTHEW T. MCLEAY
- Web page: https://patentgrep.com/patent/US20260306422A1

## CPC

- A61K 31/02: Halogenated hydrocarbons
- A61K 9/0043: {Nose}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 38/44: Oxidoreductases (1)
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions for the treatment of acute manifestations because of oxidative injury by reactive oxygen species (ROS) and chronic development of fibrosis are provided. Compositions of the present invention include perfluorocarbon, hydrogen and oxygen gas, N-acetylcysteine, and glycine to counter robust oxidative responses unleashed following injury from both mechanical and non-mechanical conditions. Methods are also disclosed for delivery to challenging locations (olfactory cleft, spinal canal) and in hostile conditions (post trauma brain, spine, and upper and lower airways), with the invention's products “calming” inflamed tissue by neutralizing ROS in both acute and later complications. Active pharmaceutical ingredient(s) can also be employed to provide both acute and chronic benefit, and such active ingredients themselves can be augmented by the composition, enabling increased drug uptake and oxygenation. The present invention provides broad relief in many conditions for both human and companion subjects.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a perfluorocarbon;
0.5% to 4% (w/w) hydrogen gas;
10% to 96% (w/w) oxygen gas;
N-acetylcysteine or N-acetylcysteine amide; and
glycine.

### Claim 2 (depends on 1)

The composition of claim 1, wherein:
said perfluorocarbon comprises perflubron.

### Claim 3 (depends on 2)

The composition of claim 2, wherein:
said perflubron is in the amount of 0.1 mL to 20 mL.

### Claim 4 (depends on 1)

The composition of claim 1, wherein:
said N-acetylcysteine or N-acetylcysteine amide comprises N-acetylcysteine amide in the amount of 100 mg/mL to 600 mg/mL.

### Claim 5 (depends on 1)

The composition of claim 1, wherein:
said glycine is in the amount of 100 mg/mL to 600 mg/mL.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising:
catalase.

### Claim 7 (depends on 1)

The composition of claim 1, wherein:
said composition is one selected from the group consisting of: a dry powder, a liquid, a foam, an aerosol, a hydrogel, and an emulsion.

### Claim 8 (depends on 1)

The composition of claim 1, wherein:
said composition is configured for delivery to a target tissue by one selected from the group consisting of: a syringe, an inhaler, and a spray catheter.

### Claim 9 (depends on 1)

The composition of claim 1, further comprising:
one selected from the group consisting of: verteporfin, ribavirin, gemcitabine, aminolevulinate, acetylcysteine high molecular weight hyaluronan, monoclonal antibodies, tyrosine kinase inhibitors, nintedanib, pirfenidone, exosomal siRNA, exosomal DNA, IRDye700DX, IRDye800CW, indocyanine green (ICG), and combinations thereof.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising:
a transplant preservative fluid.

### Claim 11 (depends on 1)

The composition of claim 1, wherein:
said composition comprises a dry powder composition comprising 0 to 4% (w/w) water and having particles with a mean diameter of 0.1 microns to 5 microns.

### Claim 12 (depends on 1)

The composition of claim 1, further comprising:
a checkpoint inhibitor selected from the group consisting of: pembrolizumab, nivolumab, durvalumab, cemiplimab, tremelimumab, retifanlimab, atezolizumab, avelumab, dostarlimab, toripalimab, and combinations thereof.

### Claim 13 (depends on 1)

The composition of claim 1, further comprising:
an excipient selected from the group consisting of: a sugar, an amino acid, a sugar alcohol, a haloalkane, a self-assembling small molecule, an inorganic salt, a surfactant, and combinations thereof.

### Claim 14 (depends on 1)

The composition of claim 1, further comprising:
an emulsifier.

### Claim 15

A method of treating a medical condition comprising:
administering a perfluorocarbon, N-acetylcysteine or N-acetylcysteine amide, and glycine to a target tissue; and
administering hydrogen gas and oxygen gas to said target tissue.

### Claim 16 (depends on 15)

The method of claim 15, wherein:
said medical condition is one selected from the group consisting of: traumatic brain injury, spinal cord injury, acute respiratory distress syndrome (ARDS), and transplant ischemia and dysfunction.

### Claim 17 (depends on 15)

The method of claim 15, wherein:
said administering steps comprise intranasal administration of said perfluorocarbon, N-acetylcysteine or N-acetylcysteine amide, and glycine and intranasal administration of said hydrogen gas and said oxygen gas.

### Claim 18 (depends on 17)

The method of claim 17, further comprising:
positioning a patient in supine position to enable delivery of said perfluorocarbon, N-acetylcysteine or N-acetylcysteine amide, glycine, hydrogen gas, and oxygen gas to an olfactory cleft of said patient.

### Claim 19 (depends on 15)

The method of claim 15, wherein:
said administering steps comprise instilling said perfluorocarbon, N-acetylcysteine or N-acetylcysteine amide, and glycine into a procured organ for transplant and instilling said hydrogen gas and said oxygen gas into said procured organ for transfer as static cold storage or as a perfusate for ex vivo perfusion in hypothermic conditions.

### Claim 20 (depends on 15)

The method of claim 15, further comprising:
measuring exhaled nitric oxide (eNO) in a patient to determine severity of reactive oxygen species (ROS).
